We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Q1 Earnings Have Liftoff: IBM, UAL, LRCX, CSX & ISRG
Read MoreHide Full Article
After the closing bell Tuesday, a fresh wave of Q1 earnings reports have come out, across a wide swath of sectors. Among the big names posting actuals this afternoon, all came out with exclusively better-than-expected results.
IBM Corp. (IBM - Free Report) , at first glance, appeared to accomplish what analyst had set out for it: a 5-cent earnings beat to $2.45 per share on $19.1 billion in sales, which surpassed the $18.7 analysts were looking for. These figures represent year-over-year revenue growth for the first time in 5 years, but after-market trading is selling off IBM shares roughly 5%, virtually wiping out the company's gains for all of 2018 so far.
This sell-off may also provide a drag to the Dow index tomorrow morning, which had just finally dug itself out of its hole over the past month. IBM's guidance for full-year 2018 was reaffirmed at $13.80 per share; apparently investors were looking for something a little stronger on this line.
United Continental (UAL - Free Report) topped the Zacks consensus earnings estimate by a penny to 50 cents a share, with revenues for the quarter also edging out expectations to $9.03 billion. This marks a 23% upswing in earnings from the year-ago quarter on PRASM metrics up 2.7% in Q1. Full-year guidance have tightened to between $7-8 per share, and the company has beaten estimates on the bottom line for 5 straight quarters.
Lam Research (LRCX - Free Report) also outperformed estimates, though not by as impressive of margins as some of these companies this afternoon. Headline numbers of $4.79 per share on $2.89 billion in sales also mark the fifth-straight earnings beat, and revenue growth year over year was roughly 33%. Yet late trading is selling the news following a strong regular session, down 2.6% since results were posted. For more on LRCX's earnings, click here.
CSX Corp. (CSX - Free Report) easily bettered expectations on the bottom line in its Q1 -- 78 cents per share vs. 66 cents expected, on $2.88 billion in revenues, better than the $2.83 billion expected. This company has also outperformed in the past 5 straight quarters, with a trailing 4-quarter average of over 10%. Late trading is pushing up CSX shares 3.78%.
Finally, Intuitive Surgical (ISRG - Free Report) posted arguably the most impressive Q1 report of the bunch, with $2.44 per share far outpacing the $1.99 expected, and revenues of $848 million solidly passing the $767 million in the Zacks consensus. Shares in late trading are up 5.6%, putting the MedTech company up near record-high trading territory.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Image: Bigstock
Q1 Earnings Have Liftoff: IBM, UAL, LRCX, CSX & ISRG
After the closing bell Tuesday, a fresh wave of Q1 earnings reports have come out, across a wide swath of sectors. Among the big names posting actuals this afternoon, all came out with exclusively better-than-expected results.
IBM Corp. (IBM - Free Report) , at first glance, appeared to accomplish what analyst had set out for it: a 5-cent earnings beat to $2.45 per share on $19.1 billion in sales, which surpassed the $18.7 analysts were looking for. These figures represent year-over-year revenue growth for the first time in 5 years, but after-market trading is selling off IBM shares roughly 5%, virtually wiping out the company's gains for all of 2018 so far.
This sell-off may also provide a drag to the Dow index tomorrow morning, which had just finally dug itself out of its hole over the past month. IBM's guidance for full-year 2018 was reaffirmed at $13.80 per share; apparently investors were looking for something a little stronger on this line.
United Continental (UAL - Free Report) topped the Zacks consensus earnings estimate by a penny to 50 cents a share, with revenues for the quarter also edging out expectations to $9.03 billion. This marks a 23% upswing in earnings from the year-ago quarter on PRASM metrics up 2.7% in Q1. Full-year guidance have tightened to between $7-8 per share, and the company has beaten estimates on the bottom line for 5 straight quarters.
Lam Research (LRCX - Free Report) also outperformed estimates, though not by as impressive of margins as some of these companies this afternoon. Headline numbers of $4.79 per share on $2.89 billion in sales also mark the fifth-straight earnings beat, and revenue growth year over year was roughly 33%. Yet late trading is selling the news following a strong regular session, down 2.6% since results were posted. For more on LRCX's earnings, click here.
CSX Corp. (CSX - Free Report) easily bettered expectations on the bottom line in its Q1 -- 78 cents per share vs. 66 cents expected, on $2.88 billion in revenues, better than the $2.83 billion expected. This company has also outperformed in the past 5 straight quarters, with a trailing 4-quarter average of over 10%. Late trading is pushing up CSX shares 3.78%.
Finally, Intuitive Surgical (ISRG - Free Report) posted arguably the most impressive Q1 report of the bunch, with $2.44 per share far outpacing the $1.99 expected, and revenues of $848 million solidly passing the $767 million in the Zacks consensus. Shares in late trading are up 5.6%, putting the MedTech company up near record-high trading territory.
Investor Alert: Breakthroughs Pending
A medical advance is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating substantial revenue, and even more wondrous products are in the pipeline.
Cures for a variety of deadly diseases are in sight, and so are big potential profits for early investors. Zacks names 5 stocks to buy now.
Click here to see them >>